DermTech’s Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium

DermTech’s Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium




DermTech’s Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion in two CME sessions, at the Fall Clinical Dermatology Virtual Grand Rounds (the “FCVGR”) and the 23rd Annual Mount Sinai Winter Symposium “Advances in Medical and Surgical Dermatology” (the “Mount Sinai Symposium”).

The FCVGR presentation was led by Laura K Ferris, MD, PhD of the University of Pittsburgh Department of Dermatology on December 2. The Mount Sinai Symposium presentation was led by George Han, MD, Chairman of the Department of Dermatology at Mount Sinai Beth Israel, on December 4, 2020.

Fall Clinical Dermatology Virtual Grand Rounds

The co-directors of the Fall Clinical Dermatology Conference created the Virtual Grand Round series to help meet the continued need for CME accreditation during uncertain times and maintain the educational opportunities that would traditionally be available at an in-person conference.

Dr. Ferris led the CME presentation “Gene Expression Profiling for Melanoma Diagnosis,” during the “Evolving Concepts in Dermatology Part XVIII,” session of the FCVGR. The presentation is available for viewing here.

Dr. Ferris commented in her presentation, “New clinical research demonstrates that 78% of lesions that are Pigmented Lesion Assay positive and therefore demonstrate genomic atypia in all cases, also have features of atypia or melanoma histopathologically.”

Mount Sinai Winter Symposium

The Mount Sinai Symposium is specifically designed to equally update the practicing dermatologists, cosmetic surgeons and other healthcare professionals on the latest advances in medical and surgical dermatology.

Dr. Han, who serves as the Director of Teledermatology for the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, led the CME presentation in the session “Using Genomics for Melanoma Diagnosis.

Dr. Han commented: “The current paradigm of evaluating pigmented lesions leaves much to be desired, both in our approach to lesions in clinical practice as well as in obtaining and evaluating biopsies for accurate diagnoses. There is great potential in using genomics to improve our approach to pigmented lesions—and with DermTech’s Pigmented Lesion Assay, we can now offer our patients a non-invasive test that improves our current sensitivity towards diagnosing melanoma. That, combined with the fact that we can utilize telemedicine to bring this test into our patients’ homes and potentially catch melanomas earlier, gives us the ability to finally make an impact on the diagnosis and mortality rate of melanoma.”

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.

Forward-looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products, including the Pigmented Lesion Assay, and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Contacts

DermTech

Sarah Dion

sdion@dermtech.com
858.450.4222

Crowe PR

Sarah Gallagher

sgallagher@crowepr.com
224.406.4709